[ad_1]
The government signed an additional purchase contract for 3 million Pfizer vaccines (6 million doses) on the 15th, and the start of supply for the first 3 quarters was advanced to the 1st quarter (end of March). In addition, a contract is signed for 20 million people (40 million doses) of the NovaVax vaccine, which has been discussing purchase contracts until now.
The Korean Centers for Disease Control and Prevention (CEO Jeong Eun-kyung) announced that they would contract an additional 23 million COVID-19 vaccines for a more stable vaccine supply in the first half.
As uncertainties in COVID-19 vaccine production and supply are increasing around the world, the volume of vaccines in the first half is particularly limited.
To prepare for the various uncertainties in the supply and demand of these vaccines, the government purchased an additional 3 million people (6 million doses) in addition to the 10 million Pfizer vaccines contracted last year (20 million doses ), resulting in a total of 13 million people (26 million doses) Pfizer signed a contract to purchase a vaccine.
In addition, the introduction of the Pfizer vaccine was initially scheduled from the third quarter, but according to the results of the first supply negotiations with pharmaceutical companies, 500,000 people (1 million doses) in the first quarter (end of March) and 3 million people (6 million doses) in the second quarter.
Currently, the Ministry of Food and Drug Safety is reviewing the approval of the Pfizer vaccine, and vaccination is scheduled to begin in April, when the approval of the national shipment for the vaccine introduced in late March is completed.
Additionally, the Korea Centers for Disease Control and Prevention (KCDC) held a signing ceremony for a COVID-19 vaccine supply contract with SK Bioscience (CEO Jae-yong Ahn) at 10:00 am on 16 February (Tuesday), serving 20 million people (40 million doses). Sign a pre-purchase contract.
President James Young will participate in the contract signing ceremony with NovaVax headquarters (USA) via video connection and will discuss cooperation plans for the production and supply of COVID-19 vaccines between the Centers Korea for Disease Control and Prevention, NovaVax and SK Bioscience. .
 |
The government has been discussing the purchase of the NovaVax vaccine in preparation for the uncertain supply and demand situation for the Corona 19 vaccine.
On February 12 (Friday), SK Bioscience signed a vaccine technology introduction contract (technology licensee) with NovaVax, and in connection with this, the Korea Centers for Disease Control and Prevention signed a contract to purchase NovaVax vaccine with SK Bioscience. The NovaVax vaccine, which has been signed with a purchase contract, will be introduced sequentially from the second quarter.
The NovaVax vaccine will be the first case of production of a Corona 19 vaccine in Korea through technology transfer. This will not only help secure the original technology for vaccine development in Korea, but will also serve as an opportunity to establish a stable vaccine supply base.
In particular, the NovaVax vaccine is a synthetic antigen method that is applied to many vaccines, such as influenza and hepatitis B, and is a new platform different from the government-bought virus and mRNA delivery system.
The synthetic antigen vaccine is a method of inducing an immune response by synthesizing an antigenic protein and administering it to the human body by mixing it with an adjuvant. It can be stored and distributed under refrigerated conditions (2 ~ 8 ℃).
“In a situation where there is much uncertainty in the supply of vaccines around the world, we will contribute to a stable supply and demand by early introduction of the NovaVax vaccine and the Pfizer vaccine that can be produced and supplied in Korea.” 20 million people (40 million doses), we have secured a total of 79 million vaccines (152 million doses) so far, and we plan to make efforts for early supply and rapid vaccination. “Reporter Choi Ji-mi
